Trial · NCT01366976
Inhibition of Lipid Peroxidation During Cardiac Surgery
NCT01366976, Not applicable, Completed, Vanderbilt University; results first posted 2015-01-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Inhibition of Lipid Peroxidation During Cardiac Surgery. Trials, record NCT01366976. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01366976
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Inhibition of Lipid Peroxidation During Cardiac Surgery
- NCT number
- NCT01366976
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 67 participants, actual
- Lead sponsor
- Vanderbilt University
- Conditions
- Cardiopulmonary Bypass Induced Lipid Peroxidation
- Interventions
- Acetaminophen
- First posted
- 2011-06-06
- Last updated
- 2015-01-27
- Results first posted
- 2015-01-14
- Limitations and caveats
The exploratory analysis of acute kidney injury (AKI) was limited by the low incidence of postoperative AKI in the current study, so we were underpowered to detect small differences in creatinine or NGAL concentrations.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Plasma Isofuran Concentrations | 24 hours | Plasma isofuran concentrations as a measure of lipid peroxidation |
| Primary | Plasma F2-isoprostane Concentrations | 24 hours | Plasma F2-isoprostane concentrations as a measure of lipid peroxidation |
| Secondary | Urinary NGAL (Neutrophil Gelatinase-associated Lipocalin) | 24 hours | Changes in urinary NGAL (neutrophil gelatinase-associated lipocalin) as marker of acute kidney injury |
| Secondary | Serum Creatinine | 72 hours | Serum creatinine measured over a 72 hour period |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Plasma Isofuran Concentrations | 24 hours | pg/mL | MEAN | |
| SECONDARY | Urinary NGAL (Neutrophil Gelatinase-associated Lipocalin) | 24 hours | ng/mL | MEAN | |
| PRIMARY | Plasma F2-isoprostane Concentrations | 24 hours | pg/mL | MEAN | |
| SECONDARY | Serum Creatinine | 72 hours | mg/dL | MEAN |
Source ClinicalTrials.gov
Results by group38
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Plasma Isofuran Concentrations | Acetaminophen | baseline | 61.5 | Standard Error 6.8 | pg/mL |
| Plasma Isofuran Concentrations | Placebo | baseline | 67.7 | Standard Error 5.97 | pg/mL |
| Plasma Isofuran Concentrations | Acetaminophen | 30min of bypass | 72.1 | Standard Error 7.37 | pg/mL |
| Plasma Isofuran Concentrations | Placebo | 30min of bypass | 82.7 | Standard Error 6.02 | pg/mL |
| Plasma Isofuran Concentrations | Acetaminophen | 60min of bypass | 83.4 | Standard Error 7.55 | pg/mL |
| Plasma Isofuran Concentrations | Placebo | 60min of bypass | 110.8 | Standard Error 13.21 | pg/mL |
| Plasma Isofuran Concentrations | Acetaminophen | post-bypass | 82.9 | Standard Error 9.71 | pg/mL |
| Plasma Isofuran Concentrations | Placebo | post-bypass | 96.1 | Standard Error 8.22 | pg/mL |
| Plasma Isofuran Concentrations | Acetaminophen | ICU | 85.3 | Standard Error 8.53 | pg/mL |
| Plasma Isofuran Concentrations | Placebo | ICU | 88.0 | Standard Error 8.81 | pg/mL |
1 to 10 of 38Source ClinicalTrials.gov
See all 38 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Acetaminophen | 30 | |
| Overall Study | STARTED | Placebo | 30 | |
| Overall Study | COMPLETED | Acetaminophen | 30 | |
| Overall Study | COMPLETED | Placebo | 30 | |
| Overall Study | NOT COMPLETED | Acetaminophen | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Postoperative atrial fibrillation | Cardiac disorders | Acetaminophen | 4 | 30 | 4 |
| other | Postoperative atrial fibrillation | Cardiac disorders | Placebo | 4 | 30 | 4 |
| other | Re-exploration for bleeding | Surgical and medical procedures | Acetaminophen | 1 | 30 | 1 |
| other | Re-exploration for bleeding | Surgical and medical procedures | Placebo | 1 | 30 | 1 |
| other | Acute kidney injury | Renal and urinary disorders | Acetaminophen | 3 | 30 | 3 |
| other | Acute kidney injury | Renal and urinary disorders | Placebo | 3 | 30 | 3 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Acetaminophen | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Acetaminophen | 4 | 30 |
| Total, other adverse events | Placebo | 4 | 30 |
| Total, serious adverse events | Acetaminophen | 0 | 30 |
| Total, serious adverse events | Placebo | 0 | 30 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Acetaminophen vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01366976
GET https://conductscience.org/api/trials/v1/NCT01366976/results?page=2